Process for preparation of amorphous form of dasatinib
A stable amorphous form of dasatinib of Formula (I) wherein amorphous dasatinib after exposure to a relative humidity of 75% at 40 ° C. or 60% at 25 ° C. for a period of at least three months doesn't change to crystalline form and a process for the preparation of the amorphous form of dasatinib of Formula (I).
1. A process for the preparation of the amorphous form of dasatinib of Formula (I),
wherein the amorphous form is prepared by grinding a solid-solid mixture of dasatinib and a polymer.
2. The process according to claim 1 ,
wherein the amorphous dasatinib is free from residual solvents.
3. The process according to claim 1 , wherein the polymer is a non-ionic polymer or an ionic polymer.
4. The process according to claim 1 , wherein the amorphous form is prepared by grinding dasatinib of Formula (I) in the absence of a solvent.
5. The process according to claim 1 , further comprising forming a pharmaceutical composition comprising the amorphous form of dasatinib of Formula (I) with one or more pharmaceutically acceptable carriers, excipients or diluents.
6. The process according to claim 1 , further comprising forming A pharmaceutical composition comprising a therapeutically effective amount of the amorphous form of dasatinib of Formula (I), the polymer and one or more pharmaceutically acceptable carriers, excipients or diluents.
7. The process according to claim 1 , wherein grinding the solid-solid mixture is under controlled humidity.
8. The process according to claim 1 ,
wherein the amorphous dasatinib is free from residual solvents, and the amorphous form of dasatinib is stable as measured by absence of a conversion of the amorphous form of dasatinib to a crystalline form of dasatinib after the amorphous form of dasatinib is exposed to a relative humidity of 75% at 40° C. or 60% at 25° C. for a period of at least three months.
9. The process according to claim 1 , wherein the amorphous form of dasatinib is stable as measured by absence of a conversion of the amorphous form of dasatinib to a crystalline form of dasatinib after the amorphous form of dasatinib is exposed to a relative humidity of 75% at 40° C. or 60% at 25° C. for a period of at least three months.
10. The process according to claim 7 , wherein the controlled humidity is a relative humidity in the range of 50±10%.
11. The process according to claim 1 , wherein the step of grinding a solid-solid mixture of dasatinib and a polymer comprises grinding a solid-solid mixture of crystalline dasatinib and HPMC-AS.
12. The process according to claim 1 , wherein the step of grinding dasatinib comprises grinding crystalline dasatinib.
13. The process according to claim 1 , wherein the polymer comprises one or more of HPMC-AS, HPMC, methacrylic acid copolymers, and PVP.
14. The process according to claim 1 , wherein the ratio of dasatinib to polymer is about 1:1 to about 1:10.